^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Colorectal Cancer
    Drug:Lumakras (sotorasib) (KRAS G12C inhibitor)
    Drug Class:MEK inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

    Excerpt:
    ...- Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requirements....
    Trial ID:
    CodeBreak101
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of AMG 510

    Excerpt:
    ...For all parts except 2e: Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing. ...
    Trial ID:
    2018-001400-11
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2021
    Title:

    1057 - Combination of the KRASG12C inhibitor sotorasib with targeted agents improves anti-tumor efficacy in KRAS p.G12C cancer models

    Published date:
    03/10/2021
    Excerpt:
    In efficacy studies using the NCI-H358 xenograft model, significantly enhanced anti-tumor activity was observed with a minimally efficacious dose of sotorasib in combination with afatinib, RMC-4550, or a CDK4/6 inhibitor (palbociclib). Furthermore, enhanced anti-tumor activity was observed with sotorasib in combination with a MEK inhibitor or with the anti-EGFR monoclonal antibody panitumumab in a CRC KRAS p.G12C PDX model.